LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

41.01 -6.16

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

40.78

Massimo

41.38

Metriche Chiave
By Trading Economics
Entrata	-14M -130M
Vendite	-888K 143K
Margine di Profitto	-90,972.727
Dipendenti	437
EBITDA	-12M -142M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+116.11% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	454M 4.5B
Apertura precedente	47.17
Chiusura precedente	41.01

Notizie sul Sentiment di mercato

By Acuity

75%

25%

317 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 feb 2026, 23:53 UTC

Azioni calde

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

1 mar 2026, 00:00 UTC

Principali Notizie su Eventi

Trump's War on Iran Threatens to Drive Up Oil Prices and Inflation -- WSJ

28 feb 2026, 21:36 UTC

Utili

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 21:27 UTC

Principali Notizie su Eventi

Iran Strikes Could Make Fed Rate Cuts Even Less Likely -- Barrons.com

28 feb 2026, 15:20 UTC

Utili

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 feb 2026, 14:43 UTC

Utili

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 14:40 UTC

Principali Notizie su Eventi

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28 feb 2026, 14:38 UTC

Utili

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 feb 2026, 13:51 UTC

Principali Notizie su Eventi

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28 feb 2026, 13:47 UTC

Utili

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 13:44 UTC

Utili

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 feb 2026, 13:14 UTC

Utili

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 12:41 UTC

Principali Notizie su Eventi

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28 feb 2026, 10:30 UTC

Acquisizioni, Fusioni, Takeovers

All The Ways Netflix Actually Won Even Though It Lost Warner -- Heard on the Street -- WSJ

28 feb 2026, 02:32 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 feb 2026, 02:00 UTC

Acquisizioni, Fusioni, Takeovers

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 feb 2026, 02:00 UTC

Acquisizioni, Fusioni, Takeovers

Six Months, 9 Offers and $81 Billion. How -2-

28 feb 2026, 00:01 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 feb 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Utili

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Utili

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Utili

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

116.11% in crescita

Previsioni per 12 mesi

Media 88.82 USD 116.11%

Alto 105 USD

Basso 67 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

317 / 352 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.